Quick Evidence Summary
| Evidence type | Current status |
|---|---|
| Pivotal obesity trial | TRIUMPH-1: Phase 3, 80-week RCT, 2,339 adults (NCT05929066) |
| Weight loss, 12mg dose | 28.3% at 80 weeks; 30.3% in a 104-week extension cohort |
| FDA status | Investigational; targeting regulatory filing in early 2027 |
| Legal availability | Not available outside Eli Lilly's own clinical trials |
| Research-chemical market | Exists despite active trial status - a notable red flag |
What Retatrutide Is
Retatrutide (Eli Lilly's development code LY3437943) is a triple hormone-receptor agonist that activates the GIP, GLP-1, and glucagon receptors at once, building on the dual-agonist mechanism of drugs like tirzepatide and adding a third target. It's being developed by Eli Lilly for obesity, type 2 diabetes, and several related conditions, but it remains an investigational drug candidate still moving through Phase 3 trials and FDA review, not a finished, approved medicine.
The Pivotal Trial: TRIUMPH-1
Retatrutide's pivotal obesity trial, TRIUMPH-1 (NCT05929066), is a Phase 3, 80-week, randomized, placebo-controlled trial of 2,339 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes. Participants were randomized to retatrutide 4mg, 9mg, 12mg, or placebo, with doses titrated up from a 2mg starting dose roughly every four weeks. On the 12mg dose, participants achieved 28.3% weight loss at 80 weeks.
A pre-specified extension followed 532 participants with a baseline BMI of 35 or higher for an additional 24 weeks (104 weeks total), dosed up to their maximum tolerated dose. Participants who stayed on the 12mg dose through the full extension reached 30.3% average weight loss (about 85 lb) from that subgroup's baseline. Lilly announced TRIUMPH-1's topline results on May 21, 2026, with results from the related TRIUMPH-2 and TRIUMPH-3 trials expected later in 2026.
Trial Safety Signal
In TRIUMPH-1, nausea occurred in 28.6% (4mg), 38.4% (9mg), and 42.4% (12mg) of participants versus 14.8% on placebo; diarrhea in 25.2%, 34.1%, and 32.0% versus 13.5%; vomiting in 10.6%, 22.8%, and 25.3% versus 4.8%. Discontinuation due to adverse events rose with dose, from 4.1% (4mg) to 11.3% (12mg), versus 4.9% on placebo. This dose-dependent gastrointestinal pattern is consistent with what's reported for tirzepatide and other incretin-based drugs, most pronounced during dose escalation.
Strong Trial Data Doesn't Mean It's Approved or Legal to Buy
Retatrutide is not approved by the FDA or any other regulator anywhere in the world. It remains in Phase 3 trials, with Lilly targeting a regulatory filing in early 2027 and approval, if granted, unlikely before late 2027. Despite that unapproved status, material labeled "retatrutide" is already sold by some suppliers as a research chemical, not for human consumption, while the real drug remains inside Lilly's own controlled trial program.
Why this matters: this is a bigger red flag than most unapproved research peptides. It means a known, actively studied drug candidate is being diverted or replicated outside the manufacturing, purity, and dosing controls of its own trial, and the FDA has issued warning letters over exactly this pattern. Strong Phase 3 data describes the real drug inside Lilly's trial; it says nothing about the purity or dosing accuracy of a vial purchased outside it.
Bloodwork to Track
TRIUMPH-1 tracked standard metabolic and GI-tolerability markers given retatrutide's triple-receptor mechanism. See the peptide bloodwork guide for what a baseline panel typically includes.
Related Reading
For the full regulatory timeline and research landscape, see the Retatrutide reference page. For how its trial data compares directly to an FDA-approved dual agonist, see Retatrutide vs Tirzepatide. BioStackIQ's Rate My Stack can help you think through where a compound like this fits into a broader stack, with this evidence picture in mind.